Market Research Logo

Top 25 Antibiotic Drugs Manufacturers 2018

Top 25 Antibiotic Drugs Manufacturers 2018

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 181 tables and 111 figures– all unavailable elsewhere.

The 250-page report provides clear detailed insight into the top 25 antibiotic drugs manufacturers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Antibiotic Drugs Market Forecast from 2018-2028, further segmented by type:
  • Cephalosporins
  • Penicillins
  • Fluoroquinolones
  • Macrolides
  • Carbapenems
  • Others
  • This report provides analysis of the leading antibiotic drugs manufacturers in the US, including forecasts from 2018-2028 of the company’s antibiotic drugs revenues, where possible:
  • Pfizer: Sulperazon, Unasyn, Zithromax, Dalacin, Merrem/Meropen, Zyvox, Tygacil, Others
  • Merck & Co.: Cubicin, Invanz, Avelox, Primaxin, Others
  • Johnson & Johnson: Zeftera, Sirturo, Others
  • Cubist Pharmaceuticals: Cubicin, Sivextro Oral
  • Abbott Laboratories: Baxin, Others
  • Eli Lilly & Co.: Vancocin, Ceclor
  • Melinta Therapeutics, Inc: Orbactiv, Others
  • This report provides analysis of the leading antibiotic drugs manufacturers in Europe, including forecasts from 2018-2028 of the company’s antibiotic drugs revenues, where possible:
  • Novartis: Vigamox, Ciprodex, TOBI Podhaler, Cubicin
  • GlaxoSmithKline: Ceftin/Zinnat, Augmentin IR, Amoxil, Others
  • Bayer: Avelox, Cipro/Cirpobay
  • Allergan: Zinforo/Teflaro, Dalbavancin, Others
  • Roche: Rocephin
  • Sanofi: Targocid, Others
  • STADA Arzneimittel: Amoxicillin, Diclofenac Sodium
  • This report provides analysis of the leading antibiotic drugs manufacturers in Japan, including forecasts from 2018-2028 of the company’s antibiotic drugs revenues, where possible:
  • Shionogi & Co., Ltd.: Flomox/Flumarin, Others
  • Taisho Pharmaceutical Holdings: Geninax, Biaxin/Clarith, Zosyn/Tazocin
  • Daiichi Sankyo: Cravit, Levaquin, Others
  • Meiji Holdings Company, Ltd.: Meiact/Spectracef, Others
  • Astellas Pharma: Dificid, Others
  • This report provides analysis of the leading antibiotic drugs manufacturers in other countries, including forecasts from 2018-2028 of the company’s antibiotic drugs revenue, where possible:
  • Sun Pharmaceutical Industries: Ciprofloxacin Hydrochloride, Others
  • Cipla: Amoxicillin, Others
  • Lupin: Cefixime, Cephalexin, Others
  • Shanghai Pharmaceuticals Holding: Cefotaxime Sodium, Cefotiam Hydrochloride, Ceftriaxone Sodium
  • Dr. Reddy’s Laboratories: Cefotaxime Sodium, Cefotiam Hydrochloride, Ceftriaxone Sodium
  • TaiGen Biotechnology: Taigexyn
Visiongain’s study is intended for anyone requiring commercial analyses for the top 25 antibiotic drugs manufacturers. You find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1. Report Overview
1.1 Global Antibiotics Drugs Manufacturer Market Overview
1.2 Overview of Findings
1.3 Structure of the Report
1.4 Global Antibiotics Drugs Manufacturer Market Segmentation
1.5 Why You Should Read This Report
1.6 Key Questions Answered by This Analytical Report
1.7 Who is This Report For?
1.8 Methodology
1.9 Associated Visiongain Report
1.10 About Visiongain
2. Introduction to Antibiotics Drugs Manufacturer
2.1 An Introduction to Antibiotics Drugs Manufacturer
2.1.1. Cephalosporins
2.1.2. Penicillins
2.1.3. Quinolones/Fluoroquinolones
2.1.4. Macrolides
2.1.5. Carbapenems
2.2. Antibiotics Drugs Manufacturer Market: Drivers, Restrains and Opportunities
2.2.1. Drivers
2.2.1.1. Need of new broad-spectrum agents
2.2.1.2. Increase in Government Funding
2.2.1.3. Infection control in health care settings
2.2.1.4. Rapidly growing antibacterial resistance
2.2.2. Restrains
2.2.2.1. Inappropriate prescription and patient compliance
2.2.2.2. Lack of return on investment
2.2.3. Opportunities
2.2.3.1. Public-Private Funding
3. Antibiotics Drugs: World Market 2018-2028
3.1 Global Antibiotics Drugs Market Forecast, 2018-2028
3.2 Global Antibiotics Drugs Market, by Automation Type: Sales Forecast 2018-2028
3.3 Leading Antibiotics Drugs Manufacturer
3.4 Leading Companies in the Antibiotics Drugs Market
3.5 Antibiotics Drugs Market Segments: Sales Forecasts 2018-2028
3.5.1 Cephalosporins Drugs Market: Sales Forecast 2018-2028
3.5.2 Penicillins Drugs Market: Sales Forecast 2018-2028
3.5.3 Fluoroquinolones Drugs Market: Sales Forecast 2018-2028
3.5.4 Macrolides Drugs Market: Sales Forecast 2018-2028
3.5.5 Carbapenems Drugs Market: Sales Forecast 2018-2028
3.5.6 Others Drugs Market: Sales Forecast 2018-2028
4. Leading US Antibiotics Drugs Manufacturers 2018-2028
4.1 Pfizer, Inc.: Overview
4.1.1 Pfizer: Antibiotics Drugs Portfolio
4.1.2 Pfizer Antibiotics Drug Sales Forecast 2018-2028
4.1.2.1 Sulperazon
4.1.2.2 Sulperazon: Sales Forecast 2018-2028
4.1.2.3 Unasyn
4.1.2.4 Unasyn: Sales Forecast 2018-2028
4.1.2.5 Zithromax
4.1.2.6 Zithromax: Sales Forecast 2018-2028
4.1.2.7 Dalacin
4.1.2.8 Dalacin: Sales Forecast 2018-2028
4.1.2.9 Merrem/Meropen
4.1.2.10 Merrem/Meropen: Sales Forecast 2018-2028
4.1.2.11 Zyvox
4.1.2.12 Zyvox: Sales Forecast 2018-2028
4.1.2.13 Tygacil
4.1.2.14 Tygacil: Sales Forecast 2018-2028
4.1.2.15 Others
4.1.2.16 Others: Sales Forecast 2018-2028
4.1.3 Pfizer: SWOT Analysis
4.2 Merck & Co.: Overview
4.2.1 Merck & Co.: Antibiotics Drugs Portfolio
4.2.2 Merck & Co. Antibiotics Drug Sales Forecast 2018-2028
4.2.2.1 Cubicin
4.2.2.2 Cubicin: Sales Forecast 2018-2028
4.2.2.3 Invanz
4.2.2.4 Invanz: Sales Forecast 2018-2028
4.2.2.5 Avelox
4.2.2.6 Avelox: Sales Forecast 2018-2028
4.2.2.7 Primaxin
4.2.2.8 Primaxin: Sales Forecast 2018-2028
4.2.2.9 Others
4.2.2.10 Others: Sales Forecast 2018-2028
4.2.3. Merck & Co.: SWOT Analysis
4.3 Johnson & Johnson: Overview
4.3.1 Johnson & Johnson: Antibiotics Drugs Portfolio
4.3.2 Johnson & Johnson Antibiotics Drug Sales Forecast 2018-2028
4.3.2.1 Zeftera
4.3.2.2 Zeftera: Sales Forecast 2018-2028
4.3.2.3 Sirturo
4.3.2.4 Sirturo: Sales Forecast 2018-2028
4.3.2.5 Others
4.3.2.6 Others: Sales Forecast 2018-2028
4.3.3. Johnson & Johnson: SWOT Analysis
4.4 Cubist Pharmaceuticals: Overview
4.4.1 Cubist Pharmaceuticals: Antibiotics Drugs Portfolio
4.4.2 Cubist Pharmaceuticals Antibiotics Drug Sales Forecast 2018-2028
4.4.2.1 Cubicin
4.4.2.2 Cubicin: Sales Forecast 2018-2028
4.4.2.3 Sivextro Oral (Tedizolid)
4.4.2.4 Sivextro Oral: Sales Forecast 2018-2028
4.4.2.5 Others
4.4.2.6 Others: Sales Forecast 2018-2028
4.4.3. Cubist Pharmaceuticals.: SWOT Analysis
4.5 Abbott Laboratories: Overview
4.5.1. Abbott Laboratories: Antibiotics Drugs Portfolio
4.5.2 Abbott Laboratories Antibiotics Drug Sales Forecast 2018-2028
4.5.2.1 Baxin
4.5.2.2 Baxin: Sales Forecast 2018-2028
4.5.2.3 Others
4.5.2.4 Others: Sales Forecast 2018-2028
4.5.3. Abbott Laboratories.: SWOT Analysis
4.6 Eli Lilly & Co.: Overview
4.6.1. Eli Lilly & Co.: Antibiotics Drugs Portfolio
4.6.2 Eli Lilly & Co. Antibiotics Drug Sales Forecast 2018-2028
4.6.2.1 Vancocin
4.6.2.2 Vancocin: Sales Forecast 2018-2028
4.6.2.3 Ceclor
4.6.2.4 Ceclor: Sales Forecast 2018-2028
4.6.3. Eli Lilly & Co.: SWOT Analysis
4.7 Melinta Therapeutics, Inc.: Overview
4.7.1 Melinta Therapeutics, Inc.: Antibiotics Drugs Portfolio
4.7.2 Melinta Therapeutics, Inc. Antibiotics Drug Sales Forecast 2018-2028
4.7.2.1 Orbactiv
4.7.2.2 Orbactiv: Sales Forecast 2018-2028
4.7.2.3 Others
4.7.2.4 Others: Sales Forecast 2018-2028
4.7.3. Melinta Therapeutics, Inc: SWOT Analysis
5. Leading Europe Antibiotics Drugs Manufacturers 2018-2028
5.1 Novartis: Overview
5.1.1 Novartis: Antibiotics Drugs Portfolio
5.1.2 Novartis Antibiotics Drug Sales Forecast 2018-2028
5.1.2.1 Vigamox
5.1.2.2 Vigamox: Sales Forecast 2018-2028
5.1.2.3 Ciprodex
5.1.2.4 Ciprodex: Sales Forecast 2018-2028
5.1.2.5 TOBI Podhaler
5.1.2.6 TOBI Podhaler: Sales Forecast 2018-2028
5.1.2.7 Cubicin
5.1.2.8 Cubicin: Sales Forecast 2018-2028
5.1.3 Novartis: SWOT Analysis
5.2 GlaxoSmithKline plc: Overview
5.2.1 GlaxoSmithKline plc: Antibiotics Drugs Portfolio
5.2.2 GlaxoSmithKline plc Antibiotics Drug Sales Forecast 2018-2028
5.2.2.1 Ceftin/Zinnat
5.2.2.2 Ceftin/Zinnat: Sales Forecast 2018-2028
5.2.2.3 Augmentin IR
5.2.2.4 Augmentin IR: Sales Forecast 2018-2028
5.2.2.5 Amoxil (Amoxicillin)
5.2.2.6 Amoxil: Sales Forecast 2018-2028
5.2.2.7 Others
5.2.2.8 Others: Sales Forecast 2018-2028
5.2.3 GlaxoSmithKline plc: SWOT Analysis
5.3 Bayer AG: Overview
5.3.1 Bayer AG: Antibiotics Drugs Portfolio
5.3.2 Bayer AG Antibiotics Drug Sales Forecast 2018-2028
5.3.2.1 Avelox
5.3.2.2 Avelox: Sales Forecast 2018-2028
5.3.2.3 Cipro/Cirpobay
5.3.2.4 Cipro/Cirpobay: Sales Forecast 2018-2028
5.3.3 Bayer AG: SWOT Analysis
5.4 Allergan plc: Overview
5.4.1 Allergan plc: Antibiotics Drugs Portfolio
5.4.2 Allergan plc Antibiotics Drug Sales Forecast 2018-2028
5.4.2.1 Zinforo/Teflaro
5.4.2.2 Zinforo/Teflaro: Sales Forecast 2018-2028
5.4.2.3 Dalbavancin
5.4.2.4 Dalbavancin: Sales Forecast 2018-2028
5.4.2.5 Others
5.4.2.6 Others: Sales Forecast 2018-2028
5.4.3. Allergan plc: SWOT Analysis
5.5. F. Hoffmann-La Roche AG: Overview
5.5.1 F. Hoffmann-La Roche AG: Antibiotics Drugs Portfolio
5.5.2. F. Hoffmann-La Roche AG Antibiotics Drug Sales Forecast 2018-2028
5.5.2.1 Rocephin
5.5.2.2 Rocephin: Sales Forecast 2018-2028
5.5.3. F. Hoffmann-La Roche AG: SWOT Analysis
5.6 Sanofi: Overview
5.6.1. Sanofi: Antibiotics Drugs Portfolio
5.6.2 Sanofi Antibiotics Drug Sales Forecast 2018-2028
5.6.2.1 Targocid
5.6.2.2 Targocid: Sales Forecast 2018-2028
5.6.2.3 Others
5.6.2.4 Others: Sales Forecast 2018-2028
5.6.3 Sanofi: SWOT Analysis
5.7 STADA Arzneimittel: Overview
5.7.1. STADA Arzneimittel: Antibiotics Drugs Portfolio
5.7.2 STADA Arzneimittel Antibiotics Drug Sales Forecast 2018-2028
5.7.2.1 Amoxicillin
5.7.2.2 Amoxicillin: Sales Forecast 2018-2028
5.7.2.3 Diclofenac Sodium
5.7.2.4 Diclofenac Sodium: Sales Forecast 2018-2028
5.7.3 STADA Arzneimittel: SWOT Analysis
6. Leading Japan Antibiotics Drugs Manufacturers 2018-2028
6.1 Shionogi & Co., Ltd.: Overview
6.2.1 Shionogi & Co., Ltd.: Antibiotics Drugs Portfolio
6.1.2 Shionogi & Co., Ltd. Antibiotics Drug Sales Forecast 2018-2028
6.1.2.1 Flomox/Flumarin
6.1.2.2 Flomox/Flumarin: Sales Forecast 2018-2028
6.1.2.3 Others
6.1.2.4 Others: Sales Forecast 2018-2028
6.1.3 Shionogi & Co., Ltd.: SWOT Analysis
6.2 Taisho Pharmaceutical Holdings: Overview
6.2.1 Taisho Pharmaceutical Holdings: Antibiotics Drugs Portfolio
6.2.2 Taisho Pharmaceutical Holdings Antibiotics Drug Sales Forecast 2018-2028
6.2.2.1 Geninax
6.2.2.2 Geninax: Sales Forecast 2018-2028
6.2.2.3 Biaxin/Clarith
6.2.2.4 Biaxin/Clarith: Sales Forecast 2018-2028
6.2.2.5 Zosyn/Tazocin
6.2.2.6 Zosyn/Tazocin: Sales Forecast 2018-2028
6.2.2.7 Other
6.2.2.8 Other: Sales Forecast 2018-2028
6.2.3. Taisho Pharmaceutical Holdings: SWOT Analysis
6.3 Daiichi Sankyo: Overview
6.3.1 Daiichi Sankyo: Antibiotics Drugs Portfolio
6.3.2 Daiichi Sankyo Antibiotics Drug Sales Forecast 2018-2028
6.3.2.1 Cravit
6.3.2.2 Cravit: Sales Forecast 2018-2028
6.3.2.3 Levaquin
6.3.2.4 Levaquin: Sales Forecast 2018-2028
6.3.2.5 Others
6.3.2.6 Others: Sales Forecast 2018-2028
6.3.3. Taisho Pharmaceutical Holdings: SWOT Analysis
6.4 Meiji Holdings Company, Ltd.: Overview
6.4.1. Meiji Holdings Company, Ltd.: Antibiotics Drugs Portfolio
6.4.2 Meiji Holdings Company, Ltd. Antibiotics Drug Sales Forecast 2018-2028
6.4.2.1 Meiact/Spectracef
6.4.2.2 Meiact/Spectracef: Sales Forecast 2018-2028
6.4.2.3 Others
6.4.2.4 Others: Sales Forecast 2018-2028
6.4.3. Meiji Holdings Company, Ltd
6.5 Astellas Pharma: Overview
6.5.1 Astellas Pharma: Antibiotics Drugs Portfolio
6.5.2 Astellas Pharma Antibiotics Drug Sales Forecast 2018-2028
6.5.2.1 Dificid
6.5.2.2 Dificid: Sales Forecast 2018-2028
6.5.2.3 Others
6.5.2.4 Others: Sales Forecast 2018-2028
6.5.3. Astellas Pharma
7. Leading Others Antibiotics Drugs Manufacturers 2018-2028
7.1 Sun Pharmaceutical Industries: Overview
7.1.1 Sun Pharmaceutical Industries: Antibiotics Drugs Portfolio
7.1.2 Sun Pharmaceutical Industries Antibiotics Drug Sales Forecast 2018-2028
7.1.2.1 Ciprofloxacin Hydrochloride
7.1.2.2 Ciprofloxacin Hydrochloride: Sales Forecast 2018-2028
7.1.2.3 Others
7.1.2.4 Others: Sales Forecast 2018-2028
7.1.3 Sun Pharmaceutical Industries: SWOT Analysis
7.2 Cipla: Overview
7.2.1 Cipla: Antibiotics Drugs Portfolio
7.2.2 Cipla Antibiotics Drug Sales Forecast 2018-2028
7.2.2.1 Amoxicillin
7.2.2.2 Amoxicillin: Sales Forecast 2018-2028
7.2.2.3 Others
7.2.2.4 Others: Sales Forecast 2018-2028
7.2.3. Cipla
7.3 Lupin Limited: Overview
7.3.1 Lupin: Antibiotics Drugs Portfolio
7.3.2 Lupin Antibiotics Drug Sales Forecast 2018-2028
7.3.2.1 Cefixime
7.3.2.2 Cefixime: Sales Forecast 2018-2028
7.3.2.3 Cephalexin
7.3.2.4 Cephalexin: Sales Forecast 2018-2028
7.3.2.5 Others
7.3.2.6 Others: Sales Forecast 2018-2028
7.3.3. Lupin: SWOT Analysis
7.4 Shanghai Pharmaceuticals Holding: Overview
7.4.1. Shanghai Pharmaceuticals Holding: Antibiotics Drugs Portfolio
7.4.2 Shanghai Pharmaceuticals Holding Antibiotics Drug Sales Forecast 2018-2028
7.4.2.1 Cefotaxime Sodium
7.4.2.2 Cefotaxime Sodium: Sales Forecast 2018-2028
7.4.2.3 Cefotiam Hydrochloride
7.4.2.4 Cefotiam Hydrochloride: Sales Forecast 2018-2028
7.4.2.5 Ceftriaxone Sodium
7.4.2.6 Ceftriaxone Sodium: Sales Forecast 2018-2028
7.4.3. Shanghai Pharmaceuticals Holding: SWOT Analysis
7.5 Dr. Reddy’s Laboratories: Overview
7.5.1 Dr. Reddy’s Laboratories: Antibiotics Drugs Portfolio
7.5.2.1 Amoxil
7.5.2.2 Amoxil: Sales Forecast 2018-2028
7.5.2.3 Ciprofloxacin Hydrochloride
7.5.2.4 Ciprofloxacin Hydrochloride: Sales Forecast 2018-2028
7.5.3. Dr. Reddy’s Laboratories: SWOT Analysis
7.6 TaiGen Biotechnology: Overview
7.6.1. TaiGen Biotechnology: Antibiotics Drugs Portfolio
7.6.2 TaiGen Biotechnology Antibiotics Drug Sales Forecast 2018-2028
7.6.2.1 Taigexyn
7.6.2.2 Taigexyn: Sales Forecast 2018-2028
7.4.3. TaiGen Biotechnology
8. Conclusions
8.1 The World Antibiotics Drugs Market in 2016 and 2017
8.1.1 Current Leading Antibiotics Drugs Segments
8.1.2 Leading Antibiotics Drugs Manufacturer Markets
8.2 World Antibiotics drugs Market Forecast 2018-2028
8.3 The Future of the Antibiotics drugs Market?
Appendix
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 3.1 Global Antibiotics Drugs Market by Product Type: Revenue ($m) and Market Share (%), 2017
Table 3.2 Global Antibiotics Drugs Market Forecast, By Automation Type: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.3 Top 10 Antibiotics Drugs Manufacturer: Revenue ($m), Market Share (%), 2017
Table 3.4 Top 25 Antibiotics Drugs Manufacturer Revenue ($m), 2017
Table 3.5 Global Antibiotics Drugs Market Forecast, By Manufacturer: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.6 Global Antibiotics Drugs Market Forecast, By Product Type: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.7 Cephalosporins Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.8 Penicillins Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.9 Fluoroquinolones Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.10 Macrolides Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.11 Carbapenems Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.12 Others Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 4.1 Pfizer, Inc.: Overview, 2018
Table 4.2 Pfizer: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
Table 4.3 Pfizer Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.4 Pfizer: Sulperazon Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.5 Pfizer: Unasyn Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.6 Pfizer: Zithromax Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.7 Pfizer: Dalacin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.8 Pfizer: Merrem/Meropen Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.9 Pfizer: Zyvox Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.10 Pfizer: Tygacil Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.11 Pfizer: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.12 Pfizer: Antibiotics Drugs Market SWOT Analysis, 2018-2028
Table 4.13 Merck & Co.: Overview, 2018
Table 4.14 Merck & Co.: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
Table 4.15 Merck & Co. Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.16 Merck & Co.: Cubicin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.17 Merck & Co.: Invanz Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.18 Merck & Co.: Avelox Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.19 Merck & Co.: Primaxin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.20 Merck & Co.: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.21 Merck & Co.: Antibiotics Drugs Market SWOT Analysis, 2018-2028
Table 4.22 Johnson & Johnson: Overview, 2018
Table 4.23 Johnson & Johnson: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
Table 4.24 Johnson & Johnson Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.25 Johnson & Johnson: Zeftera Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.26 Johnson & Johnson: Sirturo Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.27 Johnson & Johnson: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.28 Johnson & Johnson: Antibiotics Drugs Market SWOT Analysis, 2018-2028
Table 4.29 Cubist Pharmaceuticals: Overview, 2018
Table 4.30 Cubist Pharmaceuticals: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
Table 4.31 Cubist Pharmaceuticals Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.32 Cubist Pharmaceuticals: Cubicin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.33 Cubist Pharmaceuticals: Sivextro Oral Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.34 Cubist Pharmaceuticals: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.35 Cubist Pharmaceuticals: Antibiotics Drugs Market SWOT Analysis, 2018-2028
Table 4.36 Abbott Laboratories: Overview, 2018
Table 4.37 Abbott Laboratories: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
Table 4.38 Abbott Laboratories Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.39 Abbott Laboratories: Baxin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.40 Abbott Laboratories: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.41 Abbott Laboratories: Antibiotics Drugs Market SWOT Analysis, 2018-2028
Table 4.42 Eli Lilly & Co.: Overview, 2018
Table 4.43 Eli Lilly & Co.: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
Table 4.44 Eli Lilly & Co. Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.45 Eli Lilly & Co.: Vancocin Revenue ($m), AGR (%) and CAGR (%), 2016-2028
Table 4.46 Eli Lilly & Co.: Ceclor Revenue ($m), AGR (%) and CAGR (%), 2016-2021
Table 4.47 Eli Lilly & Co.: Antibiotics Drugs Market SWOT Analysis, 2018-2028
Table 4.48 Melinta Therapeutics, Inc.: Overview, 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report